



Foundation Medicine, Inc.  
Investor Relations Department  
150 Second Street  
Cambridge, MA 02141  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: FMI

|               |                                 |
|---------------|---------------------------------|
| Last Trade:   | 63.80                           |
| Trade Time:   | 4:00 PM ET<br>December 11, 2017 |
| Change:       | -3.30  (-4.918%)                |
| Day Range     | 63.28 - 69.07                   |
| 52-Week Range | 17.10 - 70.75                   |
| Volume        | 335,849                         |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Foundation Medicine is a commercial-stage company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient's individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company's first clinical product, [FoundationOne™](#), is the only commercially available comprehensive molecular infor... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

December 6, 2017

[Foundation Medicine and Collaborators to Present New Data at the American Society of Hematology \(ASH\) Annual Meeting that Supports Use of FoundationOne@Heme to Advance Personalized Medicine in Blood Cancers](#)

November 30, 2017

[FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics](#)

November 1, 2017

[Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights](#)

October 16, 2017

[Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care](#)

October 12, 2017

[Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

March 3, 2017

[Annual Report \(10-K\)](#)

April 28, 2017

[Proxy Statement \(DEF 14A\)](#)

November 1, 2017

[Quarterly Report \(10-Q\)](#)

August 1, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)